VASCADE 5F Vascular Closure System
Cardiva Medical, Inc. · Decision date Sep 10, 2026
What did the FDA decide?
The FDA recorded decision OK30 on 2026-09-10 for P120016/S043, a 30-Day Notice supplement to the VASCADE 5F Vascular Closure System (Model 700-500DX) held by Cardiva Medical, Inc. The supplement reason is listed as a process change covering manufacturer, sterilizer, packager or supplier. The recorded statement describes an additional supplier for the collagen plug component of the device.
This action concerns the supply arrangement for one component rather than a new approval of the whole system. The device is categorized as a vascular hemostasis device in the cardiovascular specialty under product code MGB. The source record does not identify the added supplier, the site involved, or any supporting documents, and it gives no clinical or performance data; those details remain unknown from this record.
Whether the supplier change affects collagen plug performance or requires further review is not addressed in the available fields, so no clinical or legal conclusion is drawn here.
FDA approval order statement
an additional supplier for the collagen plug component of the VASCADE 5F (Model 700-500DX)
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 10, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P120016/S043
- Regulatory pathway
- PMA supplement
- Applicant
- Cardiva Medical, Inc.
- Product code
- MGB
- Decision code
- OK30
- Decision date
- Sep 10, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Device, hemostasis, vascular.
- Applicant
- Cardiva Medical, Inc.
- Product code
- MGB
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P120016. Subsequent supplements may change the device or its indications.
FDA decision timeline
P120016 · Original PMA
VASCADE VASCULAR CLOSURE SYSTEM
P120016/S043 received
Application receipt date recorded by FDA.
P120016/S043 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P120016. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P120016
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Cardiva Medical, Inc. | PMA approval | Jan 31, 2013 | FDA |
Explore the linked device profile
Other records with product code MGB
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Abbott Vascular, Inc. | PMA supplement | Nov 4, 2026 | FDA | |
CELT ACD VASCULAR CLOSURE DEVICEP150006/S009 | Vasorum, Ltd. | PMA supplement | Oct 30, 2026 | FDA |
| Abbott Vascular, Inc. | PMA supplement | Oct 26, 2026 | FDA | |
| Vivasure Medical , Ltd. | PMA approval | Oct 16, 2026 | FDA | |
| Abbott Vascular, Inc. | PMA supplement | Sep 24, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Cardiva Medical, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 2900 Lakeside Dr., Suite 160, Santa Clara, CA, 95054
Sources and methodology
- Original FDA record: P120016/S043
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


